Open-Label Natalizumab Safety Extension Study
NCT00276172
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1615
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
Natalizumab
Sponsor
Biogen